## Title: Analysis of colorectal cancer microenvironment in the FinCRC cohort

## **Authors:**

<u>Iida Salonen</u><sup>1,2</sup>, Kaisa Lehtomäki<sup>1,3</sup>, Aliisa Tiihonen<sup>1,2</sup>, Reetta Särkelä<sup>1,2</sup>, Ivana Kholová<sup>1,4,5</sup>, Masi Valkonen<sup>1,2,6</sup>, Maarit Ahtiainen<sup>7</sup>, Teijo Kuopio<sup>8,9</sup>, Tiia Ilomäki<sup>1,2</sup>, Sonja Mäntylä<sup>1,2</sup>, Amanda Laurila<sup>1,2</sup>, Pekka Ruusuvuori<sup>1,2,6</sup>, Juha Väyrynen<sup>10</sup>, Pia Österlund<sup>1,3,11,12,13</sup>, Juha Kononen<sup>8,14</sup>, Kirsi Rautajoki<sup>1,2</sup>, Pirkko-Liisa Kellokumpu-Lehtinen<sup>1,2,15</sup>

## **Keywords:**

cancer, immunology, multiplex immunohistochemistry, spatial analysis, tumor microenvironment

## **Abstract**

Colorectal cancer (CRC) is the third most common and the second most lethal cancer in the world. Despite curative-intent surgery of localized stage I-III cancer, 5-33% of CRCs get a local recurrence or distant metastases. The CRC tumor microenvironment (TME) contains different cell types and structures, and actively affects the behavior of the disease. Previous data show differences in respect to tumor and lymph node status, mismatch repair, and tumor location (right-sided colon, left-sided colon or rectum, respectively). In this project, we study how the TME is associated with these factors in the Finnish CRC study.

We stained in total 531 tissue microarray (TMA) cores from 81 curatively resected patients and from metachronous metastases of 6 relapses with multiplex immunohistochemistry. Staining data of 14 protein markers from each tissue section was used to identify cancer cells and 11 different non-malignant cell types with a machine learning-based cell classifier.

Results show the TME differing based on the original tumor location. Primaries located on the right side have a higher density of CD163- macrophages compared to that of the left side and rectum (p<0.05 and p<0.01 Wilcoxon, respectively). Cell distance analysis showed that the

<sup>&</sup>lt;sup>1</sup> Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

<sup>&</sup>lt;sup>2</sup> Tays Cancer Centre, Tampere University Hospital, Tampere, Finland

<sup>&</sup>lt;sup>3</sup> Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland

<sup>&</sup>lt;sup>4</sup> Pathology, Fimlab Laboratories, Tampere, Finland

<sup>&</sup>lt;sup>5</sup> Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland and Department of Clinical Pathology, Diagnostic Imaging Center, Kuopio University Hospital, Kuopio, Finland

<sup>&</sup>lt;sup>6</sup> Institute of Biomedicine, University of Turku, Turku, Finland

<sup>&</sup>lt;sup>7</sup> Central Finland Biobank, Jyväskylä, Finland

<sup>&</sup>lt;sup>8</sup> Department of Pathology, Hospital Nova of Central Finland, Well Being Services County of Central Finland, Jyväskylä, Finland.

<sup>&</sup>lt;sup>9</sup> Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä, Finland.

<sup>&</sup>lt;sup>10</sup> Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland

<sup>&</sup>lt;sup>11</sup> Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, Finland

<sup>&</sup>lt;sup>12</sup> Department of Gastrointestinal Oncology, Tema Cancer, Karolinska University Hospital, Solna, Sweden

<sup>&</sup>lt;sup>13</sup> Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden

<sup>&</sup>lt;sup>14</sup> Docrates Cancer Center, Helsinki, Finland

<sup>&</sup>lt;sup>15</sup> Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland

Abstract — MET Research Day 2025

CD163- macrophages in the tumors originating from the right side interact more with CD8+ T-cells, compared to those located on the left side and rectum (both p<0.05, Wilcoxon). Analyses of larger cellular neighborhoods are still ongoing to discover new prognostic and predictive tools for clinical practice.